SynthesisPharmacotherapy2022
Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
Synthesis in Pharmacotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools.Clinical pharmacokinetics · 2026Pooled it
- Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.Pharmacotherapy · 2022Pooled it
- A Multicenter Randomized Controlled Study on Pharmacokinetic-Guided Vancomycin Use in Children With Severe Infections.Clinical and translational science · 2025Trial
- Implementation of a Pharmacist-Driven Vancomycin Area Under the Concentration-Time Curve Monitoring Program Using Bayesian Modeling in Outpatient Parenteral Antimicrobial Therapy.Open forum infectious diseases · 2024Trial
- Observed Trough-Based Vancomycin Dosing Decisions Versus Model-Predicted Bayesian AUC-Guided Recommendations.Healthcare (Basel, Switzerland) · 2026Article
- Model-informed AUC-guided dosing for parenteral vancomycin in critically ill patients: impact on target attainment and renal safety - a pre-post intervention study.BMC pharmacology & toxicology · 2026Article
- Article
- Evaluation of Vancomycin Therapeutic Drug Monitoring Strategies: Pharmacokinetic, Pharmacogenetic, and Clinical Perspectives in a Prospective, Real-World Cohort Study.European journal of clinical pharmacology · 2026Article
- Intra-Individual Variability of Vancomycin Trough Concentrations Before and After Implementation of a Standardized Operating Procedure in Orthopedic Inpatients.Antibiotics (Basel, Switzerland) · 2026Article
- Dual therapeutic interventions to optimize vancomycin exposure and reduce nephrotoxicity: a cohort study from a single center.BMC nephrology · 2026Article
- Prospective evaluation of individualized vancomycin dosing based on a population pharmacokinetic model in patients with severe Gram-positive bacterial infection.Frontiers in pharmacology · 2026Article
- Optimizing vancomycin therapy: the critical role of dosing frequency, AUC monitoring and gender: a retrospective cohort study.Frontiers in pharmacology · 2026Article
- Towards precision dosing of vancomycin in patients with allogeneic hematopoietic stem cell transplantation: a comparison of published population pharmacokinetic models.Antimicrobial agents and chemotherapy · 2025Article
- A pilot study evaluating mid-point vancomycin concentrations to estimate pharmacokinetics and area under the curve: a prospective study.BMC infectious diseases · 2025Article
- Optimizing Safety and Efficacy of Intravenous Vancomycin Therapy in Orthopedic Inpatients Through a Standardized Dosing Protocol: A Pre-Post Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Navigating Vancomycin and Acute Kidney Injury: AUC- vs. Trough-Guided Monitoring in Initial and Steady-State Therapy.Antibiotics (Basel, Switzerland) · 2025Article
- Safe and effective use of vancomycin.Australian prescriber · 2025Review
- Effects of AUC-Based Vancomycin Therapeutic Drug Monitoring on AKI Incidence and Drug Utilization: A Propensity Score-Weighted Analysis.Journal of clinical medicine · 2025Article
- Vancomycin Area Under the Curve to Minimum Inhibitory Concentration Ratio for Treatment Effectiveness in Pediatric and Neonatal Staphylococcal Infections: A Systematic Review.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Model-informed precision dosing of vancomycin in clinical practice: an intervention development study.International journal of clinical pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Vancomycin is commonly used to treat methicillin-resistant Staphylococcus aureus infections and is known to cause nephrotoxicity. Previous Vancomycin Consensus Guidelines recommended targeting trough concentrations but the 2020 Guidelines suggest monitoring vancomycin area under the curve (AUC) given the reduced risk of acute kidney injury (AKI) at similar levels of efficacy. This meta-analysis compares vancomycin-induced AKI incidence using AUC-guided dosing strategies versus trough-based monitoring. Literature was queried from Medline (Ovid), Web of Science, and Google Scholar from database inception through November 5, 2021. Interventional or observational studies reporting the incidence of vancomycin-induced AKI between AUC- and trough-guided dosing strategies were included. In the primary analysis, the Vancomycin Consensus Guidelines definition for AKI was used if reported; otherwise, the Risk, Injury, and Failure; and Loss, and End-stage kidney disease (RIFLE) or Kidney Disease Improving Global Outcomes (KDIGO) definitions were used. The incidence of nephrotoxicity was evaluated between the two strategies using a Mantel-Haenszel random-effects model, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Subgroup analyses for adjusted ORs and AKI definitions were performed. Heterogeneity was identified using Cochrane's Q test and I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.